test are well documented. Our aim was to determine adherence to standard operating procedures (SOPs) and highlight any deviations that may have existed.
Authoritative guidelines available for the testing of LA include the International Society on Haemostasis and Thrombosis 2009 guidelines, 4 the British Committee for Standards in Haematology 2012 guidelines and the Clinical and Laboratory Standards Institute 2014 guidelines. 5 All guidelines advise the use of normalized ratios (NR), as this reduces the effects of inter-and intra-assay variation. [5] [6] [7] [8] ISTH 2009 and BSCH 2012 suggest using the normal pooled plasma (NPP) value as denominator in determining ratios. [6] [7] [8] CLSI 2014 recommends using the mean clotting time of the reference interval (RI)
for a specific assay as the denominator in calculating ratios. The rationale for using RI mean as denominator is because of interbatch differences in NPP time, for example the variability encountered between lyophilized NPP and fresh NPP batches. It also compensates for inter-and intra-assay variability (operator/reagent/analyser), as these should have been considered in establishing the RI. All three guidelines recommend the establishment of laboratory-specific RIs.
CLSI 2014 emphasizes that the RI needs to be verified with each new lot of reagents when the RI mean is used as denominator in the NR, otherwise compensation for day-to-day variation is lost.
The guideline also specifically states that normalization to the mean of the RI should only be performed if in line with manufacturers' instructions. Data from all dRVVT assays performed from January 2015 to
December 2015 were examined in a cross-sectional study. Due to the unavailability of the newer anticoagulants in public health care in our setting, none of the patients, to our knowledge, in this study was on any of the new oral anticoagulants.
| Setting
The 
| Data collection
The raw data of all dRVVT assays, performed from January 2015
to December 2015, were captured in a Microsoft Excel spreadsheet. The interpretive report for each LA panel, authorized on the Laboratory Information Service (LIS), was also noted.
| Data processing
Challenges identified during raw data capturing include the following:
• Very few dRVVT panels contained an interpretive comment.
• Discrepancies in interpretation of raw data results. The following two methods were used to interpret results:
1. The raw result (in seconds) was compared with the RI, and decision to continue to the next step was based on the interpretation as illustrated in Table 1 . The proposed interpretation for each panel is also indicated in Table 1. 2. Calculating the screen/NPP (LA1 ratio) or confirm/NPP (LA2 ratio) ratio for each assay and comparing the LA1 and LA2 ratios to the universal cut-off of 1.2 to determine whether to proceed to the next step or not (refer to Figure 1 ). The NR (LA1 ratio/LA2 ratio) was used to interpret LA panels and establish an interpretive comment, using Table 1 as guideline.
The raw data were subsequently reinterpreted, generating a new interpretive comment. The following methods were used to interpret each dRVVT panel:
• The clotting time (in seconds) was compared with the new RIs for clotting times (in seconds).
• LA1 and LA2 ratios, using NPP as denominator, were calculated for each assay. These ratios were evaluated using ≥1.2 as abnormal. The NR was determined if indicated as per Figure 1 , and an interpretive comment generated.
• LA1 and LA2 ratios, using the RI mean, were calculated for each assay. These ratios were evaluated using ≥1.2 as abnormal. The NR was determined if indicated as per Figure 1 , and an interpretive comment generated using Table 1 .
The interpretive comments for all three methods were compared.
| Statistical analysis
All analyses were performed using Microsoft Excel for Windows and STATA version 13.1 statistical software.
| RE SULTS
A total of 2273 patient samples were processed for dRVVT determination, from January 2015 to December 2015, in the NHLS TAD Haematology Laboratory.
Only 208 (9%) of the 2273 dRVVT panels had an authorized comment. Ninety (43%) of the 208 DRVVT data sets had a standard comment, but no interpretation, added to the report.
All dRVVT panels were reinterpreted, using the patient clotting time/NPP clotting time ratio. This ratio was compared with the universal cut-off ratio of ≥1.2 as abnormal, as was stated in the SOP. A total of 478 (21%) of the 2273 dRVVT panels should have had an interpretive comment added, but this was omitted from the report. This is in direct conflict with all available guidelines for dRVVT determination. These reports were reviewed, and an interpretive comment added.
TA B L E 1 Interpretation of dRVVT screen and confirm results and mixing studies results

Patient plasma
The remaining 1588 (70%) of the 2273 dRVVT panels only had a LA1 screening clotting time/LA1 NPP clotting time ratio, which was <1.2, and easily interpreted as "LA not detected."
The comparisons of the interpretive comments, using the three methods described above, are demonstrated in Tables 2 and 3 .
There was a statistically significant discrepancy between the interpretive comments when interpreting the clotting times vs ratios with NPP as denominator (P value <.05). Using ratios, determined with NPP as denominator, and calculating NRs yielded more conclusive results (LA present/not detected) than using clotting times compared with the RI. All guidelines advise using ratios for interpretation as ratios correct for inter-and intra-assay variation as well as operator variability.
There was a statistically significant discrepancy between the interpretive comments when interpreting ratios using NPP vs RI mean as denominator (P value <.05). Of the 727 (32%) of the 2273 panels that yielded an uninterpretable report, 75 (3%) of the 2273 required further testing, but no further testing was performed, as the ratio with the NPP as denominator was <1.2, and further testing was not required, as specified by the SOP. Even with this in mind, using the NPP as denominator yielded more conclusive results (LA present/not detected) that using the RI mean as interval. Table 4 demonstrates the differences in RI mean and mean of NPP clotting times. insufficient to perform further testing or the raw result in seconds was within the normal reference interval and testing was stopped, even though the ratio (LA1 or LA2 ratio) was ≥1.2.
TA B L E 3
Comparison of interpretations determined using NPP or RI mean as denominator in determining ratios (≥1.2 abnormal)
as denominator in determining ratios. Using the RI mean will negate the significant variability in clotting times obtained from different NPP batches.
The SOP for dRVVT determination was reviewed and changed to clarify interpretation of dRVVT panels and the relevant interpretive comment that should be added to the report. The sequence of steps was also changed from screen, mix, confirm to screen, confirm, mix, as suggested by the CLSI 2014 guidelines.
The previous sequence was still followed in 2015. This resulted in redundant mixing tests being performed, which in turn impacted on reagent cost. The number of redundant tests performed was determined. The reagent cost per assay was established, and reagent cost wastage was calculated.
The reagent cost wastage was determined, and information is displayed in Table 6 .
| D ISCUSS I ON
The laboratory diagnosis of LA remains challenging for many laboratories, in large due to the heterogeneity of these autoantibodies and the lack of a gold standard.
The new RI for dRVVT had a reduced upper limit, which led to erroneous reports being authorized.
Statistically significant differences exist with all methods of interpretation evaluated in this study, but using ratios, determined with NPP as denominator, proved to yield more definitive reports (LA present/not detected) than any of the other two methods.
As mentioned in the CLSI 2014 guidelines, using the RI mean as denominator in determining ratios specifies that the RI has to be verified with each lot change of reagents. 5 This practice becomes costly, especially for a laboratory in a resource-restricted country as South Africa. Therefore, it will be more beneficial for our laboratory to use the NPP as denominator in determining ratios and comparing these ratios to the universal cut-off ratio of ≥1.2 to determine the sequence of assays as well as the interpretive comment.
The SOP for Lupus Anticoagulant testing has been revised and amended to include a flow diagram (Figure 1 ) to guide operators in determining which sequence of events to follow. 
